Pulmonary arterial hypertension
Clinical trials for Pulmonary arterial hypertension explained in plain language.
Never miss a new study
Get alerted when new Pulmonary arterial hypertension trials appear
Sign up with your email to follow new studies for Pulmonary arterial hypertension, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can Device-Preserved donor lungs boost transplant success?
Disease control By invitation onlyThis registry collects data on lung transplant patients whose donor lungs were preserved and transported using the LUNGguard or BAROguard devices. Researchers track outcomes such as primary graft dysfunction, rejection, survival, ICU and hospital stays, readmissions, and time on …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: Paragonix Technologies • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Higher dose of PAH drug may keep patients out of hospital longer
Disease control OngoingThis phase 3 trial compares two doses of macitentan (75 mg vs 10 mg) in about 935 adults with pulmonary arterial hypertension. The goal is to see if the higher dose can delay serious events like hospitalization or death. Participants will be followed for several years.
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 3 • Sponsor: Actelion • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could this pill help kids with rare lung disease?
Disease control OngoingThis study tests whether adding selexipag to standard treatment can delay disease worsening in children aged 2 to 18 with pulmonary arterial hypertension (PAH). About 138 children will receive either selexipag or a placebo, plus their usual medications. The main goal is to see if…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 3 • Sponsor: Actelion • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a new dose of selexipag help kids with rare lung disease?
Disease control OngoingThis study is testing the safety and right dose of a drug called selexipag in children aged 2 to 17 with pulmonary arterial hypertension (PAH), a serious condition where blood pressure in the lungs is too high. The goal is to find a dose that works like the adult version. The stu…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 2 • Sponsor: Actelion • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a new drug keep pulmonary arterial hypertension in check over the long haul?
Disease control Expanded access (ended)This trial gives continued treatment with the experimental drug CS1 to people with pulmonary arterial hypertension who already completed an earlier study and appeared to benefit. The main goal is to check how safe and tolerable the drug is when taken for a longer period. Particip…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: Cereno Scientific AB • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New PAH drug shows promise in Long-Term safety study
Disease control OngoingThis study is testing a new medicine called PF-07868489 for people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lung arteries makes the heart work harder. The study is open-label, meaning everyone knows they are getting the drug, and it…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New inhaled powder shows promise for Long-Term PAH control
Disease control OngoingThis study is testing the long-term safety and tolerability of an inhaled treprostinil powder (TPIP) in people with pulmonary arterial hypertension (PAH). About 91 participants who completed earlier TPIP studies will receive the drug for up to several years. Researchers will moni…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 2/3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Implanted sensors could personalize PAH drug plans
Disease control OngoingThis study tests whether implanted monitors can quickly show if a new PAH drug is working. About 40 adults with stable PAH will try two different approved drug plans while their heart and lung function are tracked. The goal is to see if this approach can help doctors choose the b…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 4 • Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New inhaled drug shows promise for rare lung disease
Disease control OngoingThis study looks at the long-term safety of an inhaled drug called GB002 for people with pulmonary arterial hypertension (PAH), a serious lung condition. It includes 74 patients who already completed a previous GB002 study. Researchers will track side effects and measure how far …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 2 • Sponsor: Gossamer Bio USA, Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Tiny heart implant aims to ease strain in rare lung disease
Disease control OngoingThis early study tests a small, permanent device called the V-Wave Interatrial Shunt in 9 people with severe pulmonary arterial hypertension (PAH). The device is placed in the heart during a minimally invasive procedure to create a small opening between the upper chambers, which …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: V-Wave Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug oxacom® shows promise for treating rare lung condition
Disease control OngoingThis study tests a new drug, Oxacom®, in 200 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. The drug is given in different doses to see if it can lower pressure in the lung's blood vessels better than a placebo. The goal…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 2/3 • Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New registry follows PAH patients on orenitram in Real-World settings
Disease control OngoingThis study is a patient registry that follows 300 adults with pulmonary arterial hypertension (PAH) who are starting or recently started Orenitram. Researchers will track how well patients tolerate the drug and how it affects their daily function and symptoms over 78 weeks. The g…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New inhaled therapy aims to ease lung blood pressure
Disease control OngoingThis study tests a new inhaled drug called L606 (liposomal treprostinil) in 28 adults with pulmonary arterial hypertension or PH-ILD. The goal is to see if it is safe and tolerable when taken twice daily, both short-term and over a year. Participants either switch from another in…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 3 • Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for PAH patients: Long-Term drug safety trial opens
Disease control By invitation onlyThis study looks at the long-term safety of the drug ralinepag in people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. About 1,000 adults who were in earlier ralinepag studies can join. The goal is to see if the drug remains s…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Implantable pump for PAH drug passes safety check
Disease control OngoingThis study tests an implanted catheter and pump system that delivers Remodulin, a drug for pulmonary arterial hypertension (PAH), directly into the bloodstream. The goal is to see if this device is safe for long-term use. The trial includes 64 patients who already use the system.…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: Medtronic Cardiac Rhythm and Heart Failure • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New hope for PAH: rapid drug therapy aims to reverse heart damage
Disease control OngoingThis study tests whether quickly starting and increasing a medication called treprostinil can lower blood pressure in the lungs and improve the heart's pumping ability in people with pulmonary arterial hypertension (PAH). The trial involves 52 adults with PAH and will measure cha…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 4 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for PAH patients: sotatercept safety trial expands
Disease control OngoingThis study looks at the long-term safety of a medicine called sotatercept for people with pulmonary arterial hypertension (PAH). Participants from an earlier study can join and receive weight-based doses every 3 weeks. The main goal is to see if the medicine is safe and well-tole…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Diet and exercise may ease rare lung disease
Disease control OngoingThis study tests whether a 12-week program of exercise and diet counseling can improve insulin sensitivity and heart function in people with pulmonary arterial hypertension (PAH). The 34 participants have stable PAH and are already on standard medications. The goal is to see if l…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can exercise ease the burden of pulmonary hypertension? new study investigates
Symptom relief OngoingThis study tests whether whole-body aerobic training (like brisk walking) or isolated leg training (with weights) better improves symptoms and quality of life in people with pulmonary arterial hypertension (PAH). About 45 participants with PAH will be assigned to one of the two e…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Heart imaging may sharpen risk prediction for lung blood pressure patients
Knowledge-focused OngoingThis study looks at whether detailed heart scans (echocardiograms and MRIs) can improve how doctors predict short-term risks in people with a type of high blood pressure in the lungs (pulmonary arterial hypertension). Researchers will follow 50 adults for 6 months to see if addin…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: Istanbul University - Cerrahpasa • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Massive study aims to redefine Lung-Heart disease
Knowledge-focused OngoingThis study looks at nearly 1,200 people with or at risk for pulmonary hypertension (high blood pressure in the lungs). Researchers use many advanced tests to find new ways to classify the disease and identify biomarkers. The goal is to better understand the disease and improve fu…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Lung condition may affect brain function, new study hints
Knowledge-focused OngoingThis study looks at whether people with pulmonary arterial hypertension (PAH) have changes in thinking skills like memory and attention. Researchers will compare 30 PAH patients to healthy volunteers using computer-based tests. The goal is to better understand how PAH might affec…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: Alessandra Gorini • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Study to test finger cuff for heart monitoring in lung disease patients withdrawn before starting
Knowledge-focused CancelledThis study was designed to see if a non-invasive finger cuff device could accurately measure how well the heart pumps blood in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). The goal was to replace the usual invasive ri…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Blood test may predict lung transplant need in PH patients
Knowledge-focused OngoingThis study is collecting blood samples from 550 adults with different types of pulmonary hypertension to measure two proteins, Activin-A and FSTL3. Researchers want to see if these proteins can predict who will need a lung transplant or die within two years. The goal is to find a…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC